PML :: RARA Detection by RT-PCR, Quantitative




Test Mnemonic

APLPCR

CPT Codes

  • 81315 - QTY (1)

Aliases

  • AMPL' APL
  • APL MRD
  • APL Post-consolidation therapy testing
  • PML-RARA fusion types, A, B, B variant
  • PML-RARA long, short, variable types
  • PML-RARA S, L, V forms
  • PML::RARA fusion types
  • PML::RARA fusion types, A, B, B variant
  • PML::RARA long, short, variable types
  • PML::RARA S, L, V forms
  • PML_RARA fusion types
  • Quantitative PML
  • t(15;17)

Includes

  • PML::RARA Translocation, Source
  • PML::RARA Translocation, Result
  • PML::RARA Translocation, NCN

Performing Laboratory

ARUP


Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
5 mLWhole bloodEDTA (Lavender) RefrigeratedCritical refrigerated. Specimen must be delivered to Cleveland Clinic Laboratories by 3 p.m. EST on the day of collection. DO NOT collect the day before or the day of a major holiday. Separate specimens must be submitted when multiple tests are ordered.

Alternate Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
3 mLBone marrowEDTA (Lavender) RefrigeratedCritical refrigerated. Specimen must be delivered to Cleveland Clinic Laboratories by 3 p.m. EST on the day of collection. DO NOT collect the day before or the day of a major holiday. Separate specimens must be submitted when multiple tests are ordered.

Minimum Specimen Requirements

Volume Type Container Collect Temperature Transport Temperature Special Instructions
1 mL    Bone marrow
3 mL    Whole blood

Stability

Environmental Condition Description
Refrigerated48 hours
FrozenUnacceptable
AmbientUnacceptable

Days Performed

Varies

Turnaround Time

3 - 10 days

Methodology

Name Description
Reverse Transcription/Polymerase Chain Reaction (RT/PCR) 

Reference Range

Special Info

CRITICAL REFRIGERATED. Severely hemolyzed or clotted specimens will be rejected.

Clinical Info

Use to detect and quantitate PML::RARA fusion transcripts in individuals with acute promyelocytic leukemia. Use to monitor minimal residual disease and assess the risk of disease relapse.

Clinical Limitation

Testing is not New York state approved. This test detects fusion types 1, 2, and 3; it does NOT identify which transcript is detected.